Insights

Expanding Clinical Pipeline Eikon Therapeutics is advancing multiple clinical programs, including a systemic first-line treatment for advanced non-small cell lung cancer, which presents opportunities for partnerships in clinical trial support, biomarker development, and medical device integrations that can enhance trial efficiency.

Recent Funding and IPO Plans With a successful Series D funding of over 350 million dollars and plans to go public, Eikon is in a growth phase, creating potential sales opportunities in investor relations platforms, financial analytics, and biotech-focused communication solutions to support their expansion and investor engagement efforts.

Innovation in Drug Discovery The company's use of single-molecule imaging and machine learning to identify novel therapeutic targets aligns with the need for advanced imaging technologies, data analytics, and AI solutions, offering avenues for sales in scientific equipment, software, and research services tailored to biotech R&D lab needs.

Leadership Changes and Talent Acquisition Recent executive appointments and the hiring of key operational leaders suggest ongoing growth and strategic shifts, opening doors for recruitment marketing services, leadership development programs, and executive consulting firms to support talent acquisition and organizational scaling.

Industry Collaborations and Events Participation in major industry conferences such as J.P. Morgan Healthcare and collaborations with investors like Soros Capital highlight potential for networking, partnership development, and supply chain enhancements, including event sponsorships, industry-specific CRM solutions, and strategic alliance management tools.

Eikon Therapeutics Tech Stack

Eikon Therapeutics uses 8 technology products and services including GDPR, Cloudflare, Selenium, and more. Explore Eikon Therapeutics's tech stack below.

  • GDPR
    Certificates
  • Cloudflare
    Content Management System
  • Selenium
    Frameworks And Libraries
  • Vue.js
    Javascript Frameworks
  • Lenis
    Javascript Libraries
  • Planisware
    Project Management
  • Yoast SEO
    Search Engines
  • Autodesk
    Visualisation Software

Media & News

Eikon Therapeutics's Email Address Formats

Eikon Therapeutics uses at least 1 format(s):
Eikon Therapeutics Email FormatsExamplePercentage
LastF@eikontx.comDoeJ@eikontx.com
63%
First@eikontx.comJohn@eikontx.com
16%
First.Last@eikontx.comJohn.Doe@eikontx.com
12%
LF@eikontx.comDJ@eikontx.com
9%

Frequently Asked Questions

Where is Eikon Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Eikon Therapeutics's main headquarters is located at 230 Harriet Tubman Way Millbrae, California 94030 United States. The company has employees across 4 continents, including North AmericaEuropeSouth America.

What is Eikon Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Eikon Therapeutics's official website is eikontx.com and has social profiles on LinkedInCrunchbase.

What is Eikon Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Eikon Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Eikon Therapeutics have currently?

Minus sign iconPlus sign icon
As of March 2026, Eikon Therapeutics has approximately 398 employees across 4 continents, including North AmericaEuropeSouth America. Key team members include Chief Business Officer & General Counsel: B. T.Chief Operating Officer: M. K.Chief People Officer: B. H.. Explore Eikon Therapeutics's employee directory with LeadIQ.

What industry does Eikon Therapeutics belong to?

Minus sign iconPlus sign icon
Eikon Therapeutics operates in the Biotechnology Research industry.

What technology does Eikon Therapeutics use?

Minus sign iconPlus sign icon
Eikon Therapeutics's tech stack includes GDPRCloudflareSeleniumVue.jsLenisPlaniswareYoast SEOAutodesk.

What is Eikon Therapeutics's email format?

Minus sign iconPlus sign icon
Eikon Therapeutics's email format typically follows the pattern of LastF@eikontx.com. Find more Eikon Therapeutics email formats with LeadIQ.

How much funding has Eikon Therapeutics raised to date?

Minus sign iconPlus sign icon
As of March 2026, Eikon Therapeutics has raised $351M in funding. The last funding round occurred on Feb 26, 2025 for $351M.

When was Eikon Therapeutics founded?

Minus sign iconPlus sign icon
Eikon Therapeutics was founded in 2019.

Eikon Therapeutics

Biotechnology ResearchCalifornia, United States201-500 Employees

Eikon Therapeutics is a late-stage clinical biopharmaceutical company advancing a pipeline of potential therapies for patients with unmet medical needs. We are passionate about novel therapeutics and share the belief that a better understanding of fundamental human disease biology can lead to better medicines. We are driven to go beyond incremental improvements. Instead, our goal is to introduce new therapies into clinical practice that will improve and extend life. Our clinical programs in oncology leverage immune response modulation and synthetic lethality to improve cancer therapy, while our discovery efforts are focused on identifying novel targets through application of single-molecule imaging to the study of cancer and neurological diseases. By applying machine learning algorithms to the very large imaging data sets that emerge from our imaging platforms, we can advance our programs towards our ultimate goal of discovering and developing better medicines. 

Eikon is seeking intellectually curious, passionate, and creative team members that are eager to apply their talents to empower interdisciplinary scientific exploration and ultimately create and develop novel medicines. To learn more about open positions, please visit: https://www.eikontx.com/join-us/#open-positions

Section iconCompany Overview

Headquarters
230 Harriet Tubman Way Millbrae, California 94030 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
201-500

Section iconFunding & Financials

  • $351M

    Eikon Therapeutics has raised a total of $351M of funding over 5 rounds. Their latest funding round was raised on Feb 26, 2025 in the amount of $351M.

  • $100M$250M

    Eikon Therapeutics's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $351M

    Eikon Therapeutics has raised a total of $351M of funding over 5 rounds. Their latest funding round was raised on Feb 26, 2025 in the amount of $351M.

  • $100M$250M

    Eikon Therapeutics's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.